Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Awarded Israeli Grant to Develop microRNA-targeting Cancer Drug

Premium

Rosetta Genomics this week announced that it has been awarded a $200,000 grant along with Ramot, Tel Aviv University’s technology-transfer company, to develop microRNA-targeting cancer drugs.

According to the company, the initial focus of the alliance will be on developing a mimic of miR-34a delivered using a polymeric carrier. The miRNA is a tumor suppressor downregulated in a variety of cancers, Rosetta said.

Notably, a miR-34a mimic developed by Mirna Therapeutics is already in the clinic as a cancer treatment (GSN 5/2/2013).

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.